Onconetix Financial Statements From 2010 to 2025
| ONCO Stock | USD 0.13 0.04 23.53% |
Check Onconetix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Onconetix's main balance sheet or income statement drivers, such as , as well as many indicators such as . Onconetix financial statements analysis is a perfect complement when working with Onconetix Valuation or Volatility modules.
Onconetix |
Onconetix Company Return On Equity Analysis
Onconetix's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Onconetix Return On Equity | -2.01 |
Most of Onconetix's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onconetix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Onconetix has a Return On Equity of -2.0134. This is 91.6% lower than that of the Biotechnology sector and 94.48% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Onconetix Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Onconetix's current stock value. Our valuation model uses many indicators to compare Onconetix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Onconetix competition to find correlations between indicators driving Onconetix's intrinsic value. More Info.Onconetix is regarded fifth in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Onconetix's earnings, one of the primary drivers of an investment's value.About Onconetix Financial Statements
Onconetix investors utilize fundamental indicators, such as revenue or net income, to predict how Onconetix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Oncology Med, Inc. offer full service cancer center solutions.
Pair Trading with Onconetix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconetix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will appreciate offsetting losses from the drop in the long position's value.Moving against Onconetix Stock
| 0.78 | KRYS | Krystal Biotech | PairCorr |
| 0.68 | IVA | Inventiva Sa | PairCorr |
| 0.57 | PBH | Prestige Brand Holdings | PairCorr |
| 0.38 | MLYS | Mineralys Therapeutics, Trending | PairCorr |
| 0.36 | PEPG | PepGen | PairCorr |
The ability to find closely correlated positions to Onconetix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconetix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconetix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconetix to buy it.
The correlation of Onconetix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconetix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconetix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconetix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Onconetix Correlation against competitors. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.